Key result
Ginsenoside Rb1 improves cardiac function and reduces weight in diabetic mice via the adipocytokine pathway.
Why the study?
The role of ginsenoside Rb1 in treating diabetic cardiomyopathy remains unclear.
Does ginsenoside Rb1 improve cardiac function and metabolic parameters in diabetic mice?
Population
Diabetic mice
Comparison
Ginsenoside Rb1 treatment vs no treatment
Design
Preclinical experimental study
Follow-up
12 weeks
Loading...
Ginsenoside Rb1 may improve cardiac parameters in diabetic mice; leaves open whether adipocytokine effects translate to human diabetic cardiomyopathy.
Does ginsenoside Rb1 improve cardiac function and metabolic parameters in diabetic mice?
Ginsenoside Rb1 protects against diabetic cardiomyopathy in mice by regulating the adipocytokine pathway, reducing lipid accumulation and oxidative stress.
A 2022 study studied Diabetic cardiomyopathy. Ginsenoside Rb1 was evaluated. Ginsenoside Rb1 treatment for 12 weeks significantly reduced body weight, attenuated hyperglycemia and hyperlipidemia, and improved cardiac function in diabetic mice via the adipocytokine pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: